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Summary
We studied the relationships between genetic and epigenetic alterations in gastrointestinal cancer by integrating DNA copy
number changes determined by arbitrarily primed PCR (AP-PCR) with DNAmethylation variations estimated bymethylation-
sensitive amplified fragment length polymorphism (MS-AFLP).We analyzed about 100 different chromosomal regions by AP-
PCR and over 150 random CpG loci by MS-AFLP in human colon and gastric carcinomas. DNA hypomethylation and hyper-
methylation alterations distributed gradually and increased with cancer patient age, in contrast with the age-independent
genomic alterations. Increased DNA hypomethylation and hypermethylation correlated with increased genomic damage,
but only hypomethylation was highly significant in multivariate analyses. We conclude that age-dependent accumulation
of DNA demethylation precedes diploidy loss in a significant subset of gastrointestinal cancers.Introduction
The mutational theory of cancer, a paradigm for the last decades
(Knudson, 1971; Bishop, 1995) is being complemented and ex-
panded by recent data demonstrating the importance of epige-
netics in cancer (Jones and Laird, 1999; Jones and Baylin, 2002;
Jaenisch and Bird, 2003; Feinberg and Tycko, 2004). Genetic al-
terations inactivate tumor suppressors and activate oncogene
expression (Hanahan and Weinberg, 2000). Genetic aberrations
at the subchromosomal level are good indicators of the degree
of disorganization of the cancer cell genome and useful for can-
cer prognosis (Malkhosyan et al., 1998; Vogelstein et al., 1989).
In addition to the genetic alterations, epigenetic alterations are
also germane to carcinogenesis. Of the oncogenic alterations
in the epigenetic code (Jenuwein and Allis, 2001), the best stud-
ied have been the alterations in DNA methylation. Silencing of
transcription by CpG island promoter hypermethylation has
been linked to tumor suppressor gene inactivation (Esteller,
2002).CANCER CELL 9, 199–207, MARCH 2006 ª2006 ELSEVIER INC. DOI 10.In contrast, less is known about the impact in tumor develop-
ment or progression of DNA hypomethylation, although it was
described over 20 years ago in human tumor cells (Diala and
Hoffman, 1982; Feinberg and Vogelstein, 1983) including global
hypomethylation in tumors (Gama-Sosa et al., 1983) and has
been associated with tumorigenesis in animal systems (Eden
et al., 2003b; Gaudet et al., 2003). Quoting a recent review, ‘‘al-
though hypomethylation was the originally identified epigenetic
change in cancer, it was overlooked in preference of hyper-
methylation and is only now undergoing a renaissance’’ (Fein-
berg and Tycko, 2004). DNA hypomethylation has been pro-
posed recently to play a role in cancer gene expression
activation (Feinberg and Tycko, 2004) and in genomic instability
(Chen et al., 1998; Schulz et al., 2002; Eden et al., 2003b; Gaudet
et al., 2003; reviewed by Hoffmann and Schulz, 2005). However,
the role of hypomethylation in cancer is controversial (Yang
et al., 2003; Eden et al., 2003a), and the relationships between
DNA hypomethylation and hypermethylation, and genomic al-
terations, are essentially unexplored (Zardo et al., 2002). WeS I G N I F I C A N C E
Themain finding of this study is that DNAhypomethylation accumulateswith agingandappears to bedominant over hypermethylation
in linking epigenotype with cancer genotype (genomic damage), and with cancer phenotype (prognostic power). As the two epige-
netic alterations are estimated simultaneously with the same technique, the conclusion is warranted. We propose that age-dependent
progressive demethylation occurs by accumulation of errors of DNAmethylation replication by constitutive methyl transferases. Once
this methylation ‘‘wear and tear’’ affects some genomic sites, the risk of errors in chromosome segregation increases, leading to accu-
mulation of genomicdamageandeventually to cancer development. Cancer is a disease of aging.Ourmodel links agingandcancer
through the putative sequential relationship between epigenetic and genetic alterations.1016/j.ccr.2006.02.016 199
CpG islands may exhibit both hyper- or hypomethylation in tu-
mor cells. In normal colon tissue, about 85% to 95% of CpG
A R T I C L Ehave studied the relationships between these alterations in
colon and gastric cancer by integrating the data from two
DNA fingerprinting methods that detect tumor-specific changes
throughout the genome.
Unbiased DNA fingerprinting methods provide powerful tools
for obtaining panoramic views of the genetic and epigenetic
changes accompanying tumorigenesis. Arbitrarily primed PCR
(AP-PCR) (Welsh and McClelland, 1990) can be used to detect
tumor-specific somatic gains and losses of sequences through-
out the genome (Malkhosyan et al., 1998; Peinado et al., 1992).
Similarly, methylation-sensitive amplified fragment length poly-
morphism (MS-AFLP) (Vos et al., 1995) can simultaneously
detect DNA hypermethylation and hypomethylation in tumor
samples compared with normal tissue (Yamamoto et al., 2001).
By screening colon cancers by AP-PCR, we showed that
some tumors accumulated hundreds of thousands of somatic
mutations in microsatellite sequences and predicted that they
were due to previously unknown mutator genes (Ionov et al.,
1993). These mutator genes were soon after isolated and char-
acterized as members of the DNA mismatch repair (MMR) gene
family (Kolodner and Marsischky, 1999; Kinzler and Vogelstein,
1996). Cancer driven by mutator genes represents a ‘‘remote
control’’ mechanism for carcinogenesis, as mutator gene inacti-
vation does not immediately lead to altered cell growth or sur-
vival (Perucho et al., 1994; Perucho, 1996; Cahill et al., 1999).
Some tumors with microsatellite instability (MSI) undergo epi-
genetic silencing of hMLH1, one of the MMR mutator genes
(Kane et al., 1997). A CpG island methylator phenotype (CIMP)
was postulated to explain the somatic hypermethylation associ-
ated with silencing of hMLH1 and several tumor suppressor
genes (Toyota et al., 1999). However, by screening colon can-
cers for DNA hypermethylation alterations using MS-AFLP we
showed that they accumulated in an age-dependent and grad-
ual manner, inconsistent with an underlying methylator pheno-
type (Yamashita et al., 2003).
Thus, the use of AP-PCR (Ionov et al., 1993) and MS-AFLP
(Yamashita et al., 2003) provided evidence in favor of the muta-
tor phenotype hypothesis (Loeb, 1991) and against the methyl-
ator phenotype hypothesis (Toyota et al., 1999) for cancer,
respectively. We have now integrated the data obtained by
these unbiased DNA fingerprint methods to study the relation-
ships between DNA hypermethylation and hypomethylation
with respect to DNA copy number changes in the same gastric
and colon tumors.
Results
Genetic and epigenetic alterations in colon
and gastric cancers
The analysis of DNA copy number alterations was performed by
AP-PCR with two arbitrary primers in a series of colon cancers,
as previously described for gastric cancers (Suzuki et al., 2003).
In both gastric and colon cancers, the extent of genomic dam-
age, estimated by AP-PCR (genomic damage fraction [GDF]),
was gradual and correlated with survival. Tumors with low
GDF showed a better prognosis than tumors with high GDF, in
accordance with previous findings (Arribas et al., 1997; Suzuki
et al., 2003; Risques et al., 2003). The results were independent
of MSI status and of the cutoff point used to segregate tumors
with relative low and high levels of genomic damage, with200tumors with higher GDF always showing a worse prognosis
than tumors with lower GDF (data not shown; see below).
These colon and gastric cancers were also used for the anal-
ysis of methylation alterations by MS-AFLP (Yamamoto et al.,
2001; Yamashita et al., 2003). MS-AFLP detects both hyper-
methylation and hypomethylation events in tumors, compared
to the corresponding normal tissue. Results with representative
tumors are shown in Figure 1. Some of the bands showed con-
sistent alterations in multiple tumors. Figure 2 shows an exam-
ple of a CpG locus found hypomethylated in 18.6% of colon
and 21.8% of gastric cancers (band 5). Similarly, some bands
exhibited recurrent hypermethylation in both colon and gastric
cancers (for example, Figure 1, band 19, exhibiting frequent
hypermethylation in both gastric [40.1%] and colon [37.5%]
cancer).
Distribution of DNA hypermethylation and
hypomethylation in colon and gastric cancer
The distribution of DNA hypermethylation and hypomethylation
alterations was gradual in both colon and gastric cancers (Fig-
ure 3). There was no hint of a bimodal distribution for gastric
or colon cancer, either for hypermethylation or hypomethylation
alterations that could be used to stratify the tumors as positive or
negative for ‘‘methylator’’ or ‘‘demethylator’’ phenotypes (see
also Figures S1–S3 in the Supplemental Data available with
this article online). Tumors with high levels of hypomethylation
also exhibited high levels of hypermethylation, revealing a posi-
tive correlation between both types of alterations in gastric (p =
0.0071) and colon (p = 0.0175) cancers.
Figure 4 shows the distribution of DNA methylation alterations
in colon and gastric cancers (hypomethylation at top and hyper-
methylation at bottom) and their impact on survival by compar-
ing patients with tumors with more alterations than the median
versus those with less. High levels of hypomethylation were in-
dicators of poor prognosis in both gastric and colon cancer,
as were increased levels of genetic alterations (middle). In con-
trast with hypomethylation, the hypermethylation alterations did
not show as strong of an association with differential survival. In
gastric cancer, tumors with high levels of hypermethylation
exhibited worse survival than patients with low levels of hyper-
methylation, but in colon cancer hypermethylation did not corre-
late with survival.
MS-AFLP estimates overall level of DNA methylation
The MS-AFLP technique allows the study of DNA methylation al-
terations of hundreds of NotI sites in a particular cell genome.
Both hypermethylation and hypomethylation can be detected
in tumor tissue DNA by the relative changes of band intensities
compared with the normal tissue DNA. To test for possible
biases in the estimation of hypomethylation events by the tech-
nique, the global methylation level of CpG sites was analyzed by
the M.SssI methylase assay (Experimental Procedures). This as-
say is based on the activity of M.SssI DNA methylase, which rec-
ognizes and labels every unmethylated CpG site in the genome,
as opposed to the MS-AFLP assay, which focuses on CpG sites
located in the NotI site. Therefore, this assay provides informa-
tion about the global methylation status of the genome.
Global DNA demethylation is often observed in tumor sam-
ples (Gama-Sosa et al., 1983; Feinberg et al., 1988), whereasCANCER CELL MARCH 2006
A R T I C L EFigure 1. MS-AFLP fingerprints of colon and gastric cancer
Autoradiograms of the MS-AFLP fingerprints of three gastric (left) and three
colon tumors (right) generated by a set of primers, NotI and MseI-C. Two dif-
ferent amounts of template DNA (2 ng and 4 ng) were applied for each
sample. Numbers at center between each figure indicate the numbers as-
signed to the different fingerprint bands. Asterisks indicate bands amplified
in only some tumors. Numbers at bottom indicate total number of bands
showing hypomethylation (HYPO) and hypermethylation (HYPER) in the fin-
gerprints. Band 5, which is frequently hypomethylated in tumors with many
changes in hypomethylation, represents centromeric repetitive sequences
assigned to chromosomes 7p.11, 9p.11, 12q.11, and 20q.11. N, normal; T, tu-
mor tissue DNA. For clarity, white triangles inside the gels indicate bands
scored as altered. The triangles are inserted only in the fingerprints from
the lower amount of DNA template.CANCER CELL MARCH 2006sites are methylated. In contrast, in tumor samples a significantly
lower portion of CpG sites is methylated (between 60% and
90%) (Bariol et al., 2003). Our data on colon cancer samples
are in the same range as these previous reports. In 11 out of
25 cases, the estimated number of methylated CpG sites in
the tumor was at least 5% lower when compared to the normal
tissue (data not shown).
For comparison of the results of the global methylation of CpG
sites and the results of the MS-AFLP, the ratio between methyl-
ated CpG sites in tumor and normal tissue was calculated (ratio
mCpG). There was significant correlation between the frequency
of hypomethylated bands in the MS-AFLP and the severity of hy-
pomethylation of CpG sites accessed by the M.SssI assay (p <
0.001; Figure S4). The results demonstrated that frequent hypo-
methylation in NotI sites detected by MS-AFLP correlated well
with the global methylation status of the DNA. Therefore,
MS-AFLP provides a good estimation of the global methylation
levels of the tumor cell. Hypermethylation is not detectable by
the approach, as the CpG sites undergoing somatic hyper-
methylation are only a minor amount compared with changes
in global genome methylation. The genomic location of several re-
petitive sequences amplified by MS-AFLP is shown in Figure S5.
Epigenetic alterations are age dependent, but genetic
alterations are not
The association of genetic and epigenetic alterations with age in
gastric and colon cancers is shown in Figure 5. In both colon and
gastric cancers, hypermethylation—and, to an even greater ex-
tent, hypomethylation—showed a positive correlation with age.
Figure 2. DNA hypomethylation detected by MS-AFLP fingerprinting in co-
lon cancer
MS-AFLP analysis of colon cancer showing frequently hypomethylated
band 5 (cases shown by asterisks) representing centromeric repetitive se-
quences. Details as in Figure 1.201
A R T I C L EFigure 3. Distribution of methylation alterations
detected by MS-AFLP in gastric and colon can-
cers
Loci undergoing hypomethylation and hyper-
methylation are indicated in green and red,
respectively. The figure depicts the tumors orga-
nized by increasing numbers of total hypometh-
ylation and hypermethylation alterations (epi-
genetic damage fraction, or EDF) from top to
bottom. Loci detected by MS-AFLP can be clas-
sified in three different categories: (1) those
frequently hypomethylated (left of the graphs),
(2) those frequently hypermethylated (right of
the graphs), and (3) those with low frequency
of both alterations (middle of the graphs).202The older the cancer patients, the more hypermethylation and
hypomethylation alterations were generally detected in the tu-
mor specimens. In contrast, the genetic alterations were not
significantly associated with the age of the cancer patients (Fig-
ure 5, middle).
Epigenetic alterations correlate with genetic alterations
in gastrointestinal cancer
We then studied the relationship between the genetic and epige-
netic alterations in colon and gastric cancer by integrating the
hyper- and hypomethylation data obtained by MS-AFLP with
the GDF data obtained by AP-PCR. The results are shown in Fig-
ure 6 (see also Figure S1). In both colon and gastric cancer, high
levels of genomic damage were associated with high levels of
hypermethylation and hypomethylation. The positive correlation
was independent of the cutoff points to stratify the tumors ac-
cording to their relative differences in DNA methylation alter-
ations, although hypermethylation was not statistically signifi-
cant for all cutoffs. Multivariate analysis showed that both
hypermethylation and hypomethylation in gastric and colon can-
cer estimated by MS-AFLP correlated with the relative extent
of genomic damage estimated by AP-PCR (GDF). However,
the association of hypomethylation alterations with genomic
damage was stronger than that of hypermethylation alterations
(Figure 7).
Discussion
The main finding of this study is the dominant role of DNA hypo-
methylation over DNA hypermethylation in linking epigenotype
Figure 4. Distribution of methylation alterations in 86 gastric cancers and 64
colon cancers
Methylation alterations of 150 loci were analyzed. Grayscale boxes show
the distribution of individual alterations in hypermethylation or hypometh-
ylation. The vertical line shows the cutoff point (median) for comparison be-
tween low versus high levels of methylation alterations. Half of all gastric
(left) and colon tumors (right) were assigned to L-hyper (low hypermethyla-
tion) or L-hypo (low hypomethylation), and the other half were assigned to
H-hyper (high hypermethylation) or H-hypo (high hypomethylation).
Kaplan-Meier survival curves according to methylation alteration levels in
gastric and colon tumors (top for hypomethylation and bottom for hyper-
methylation). Kaplan-Meier survival curves according to genomic damage
fraction (GDF), calculated by AP-PCR fingerprinting, for gastric and colon
tumors (middle). The number of cases in each survival graph differ because
survival information was not available for the complete series. Empty circles:
censored cases.CANCER CELL MARCH 2006
A R T I C L Ewith cancer genotype, and with cancer phenotype. Both epige-
netic changes accumulate globally in an age-dependent fash-
ion, which contrasts with the DNA copy number alterations,
which appear independent of the age of the cancer patients (Fig-
ure 5). The age-dependent nature of tumor-specific DNA hyper-
methylation is well established (Issa et al., 1994; Issa, 1999). The
age-dependent nature of global DNA hypomethylation in gastro-
intestinal cancer is also a novel finding of this study.
The easiest explanation for these observations is that the epi-
genetic, but not the genetic alterations, occur in normal tissue
(i.e., stem cells), and they are exposed in the tumors by the
clonal expansion after neoplastic transformation. Therefore,
we conclude that the epigenetic alterations generally occur be-
fore the genetic alterations. This is consistent with previous work
showing the early occurrence of DNA hypomethylation in cancer
(Frigola et al., 2005; Ehrlich, 2002) and the age-dependent in-
crease of demethylation in normal tissues in vertebrates, includ-
ing humans (Liu et al., 2003; Richardson, 2002; Ehrlich, 2002;
Suter et al., 2004). The differential association of the epigenetic
alterations with patient survival (cancer phenotype) and geno-
mic disruption (cancer genotype) (Figures 4, 6, and 7) suggests
that somatic DNA hypomethylation has more oncogenic weight
than DNA hypermethylation. This hypothesis suggests future
Figure 5. Epigenetic but not genetic alterations correlate with cancer pa-
tient age
The figure depicts the distribution of DNA methylation alterations deter-
mined by MS-AFLP (hypomethylation at top and hypermethylation at bot-
tom) and genetic alterations (middle), according to the age of the cancer
patients. GDF, genomic damage fraction, calculated by AP-PCR finger-
printing. p value is calculated by simple regression coefficient analysis using
the Statview statistical software package.CANCER CELL MARCH 2006studies aimed to predict and influence cancer responses to
treatment.
In accordance with our previous report on colon cancer, the
distribution of DNA hypermethylation alterations in colon and
gastric cancers was gradual, with no evidence of bimodality or
drastic discontinuity consistent with the existence of major
groups of tumors with and without a methylator phenotype
(Yamashita et al., 2003) (Figures S1–S3). Similarly, DNA hypo-
methylation alterations displayed a gradual, rather than a dis-
continuous and bimodal distribution; therefore, they were also
inconsistent with an underlying pathogenic defect in the mech-
anisms for the constitutive replication of DNA methylation at
CpG sites (i.e., a ‘‘demethylator phenotype’’).
There is no information on the mechanisms responsible for the
global hypomethylation observed in human tumors (Ehrlich,
2002; Feinberg and Tycko, 2004; Hoffmann and Schulz, 2005).
Our data (Figures 3 and 4 and Figures S1–S3) suggest that
DNA demethylation of a significant proportion of CpG sites
Figure 6. Relationship between genetic and epigenetic alterations in stom-
ach and colon cancer
Both hyper- and hypomethylation somatic alterations in gastric and colon
cancer estimated by MS-AFLP correlate with the relative extent of genomic
damage estimated by AP-PCR (GDF). The tumors were compared after
dividing the groups in three different cutoff points (I–III). The comparison be-
tween the tumors with less versus more alterations than cutoff points I and III
(excluding all tumors between cutoff points I and III) was also significant for
all four different graphs (colon and gastric cancer, and hyper- and hypo-
methylation alterations). p value is calculated by unpaired Student’s
t test. The brackets are standard errors.203
A R T I C L Eoccurs as a result of a gradual and accumulative age-dependent
failure to preserve methylation replication fidelity, rather than
due to a pathological defect triggering an increased methylation
replication error rate. This ‘‘wear and tear’’ model is consistent
with the initial report confirming the existence of cellular mech-
anisms for the automatic preservation of methyldeoxycytidine
replication, but not with 100% fidelity (Wigler et al., 1981).
Whether this process occurs universally or is restricted (or fa-
vored) to cancer-prone individuals, influenced by environmental
or genetic factors, remains to be elucidated (Liu et al., 2003;
Suter et al., 2004).
Our data show that global demethylation that increases with
age, regardless of the cause, is associated with genomic dam-
age in cancer cells. One of the mechanisms by which these
errors of methylation replication may influence the genetic
Figure 7. High frequency of DNA hypomethylation associates significantly
with increased DNA copy number alterations
p value is calculated by transformation of the regression coefficient using
the Statview statistical software package.204alterations has been postulated to affect the methylation of sen-
sitive pericentromeric repetitive sequences. This could trigger
errors in recombination and chromosome replication, leading
to the observed DNA copy number alterations (Gaudet et al.,
2003; Ehrlich, 2002; Xu et al., 1999; Qu et al., 1999). A recent re-
port with cultured HCT116 colon cancer cells harboring knock-
outs of DNMT1, DNMT3B, or both DNA methyltransferases
shows that the double knockout HCT116 cells were hypomethy-
lated compared to wild-type cells, were aneuploid, and con-
tained numerous chromosomal translocations (Karpf and Mat-
sui, 2005). The task ahead is to estimate the ‘‘width’’ of
demethylation as a possible underlying cause of oncogenic ge-
nomic instability (i.e., the percentage of tumors following this
epigenetic-genetic sequence). Based on the relative proportion
of tumors and preneoplastic lesions with and without significant
hypomethylation compared with normal tissues (data not
shown), we estimate that from one-third to one-half of all tumors
may have a potential hypomethylation-genomic instability link.
The relationship between DNA hypomethylation and hyper-
methylation has not been explored. Our data show a correlation
between DNA hypomethylation and hypermethylation (Figure 3),
and based on the previous reasonings and the ‘‘dominant’’ na-
ture of hypomethylation over hypermethylation, it may be possi-
ble to speculate that hypomethylation also influences the occur-
rence of hypermethylation.
Therefore, the following model can be proposed for gastro-
intestinal cancer development, although it also may be extra-
polated to other cancers (Figure 8). In some MSI-negative tu-
mors, the gradual and age-dependent increase in global DNA
demethylation may increase the probability of occurrence of
the genomic alterations accompanying tumor development
and progression (Figure 8A).
On the other hand, in MSI-positive tumors without genetic
inactivation of MMR, a gradual and age-dependent hyper-
methylation of CpG islands of obscure origin determines the
manifestation of the mutator phenotype when hMLH1 becomes
silenced (Kane et al., 1997). Once the mutator phenotype un-
folds, cancer eventually develops (Figure 8B).
In both cases, with or without a mutator phenotype, the epige-
netic alterations appear to precede the genetic alterations. In
MSI tumors, the genetic alterations supersede the epigenetic
alterations in the manifestation of the cancer phenotype (Yama-
shita et al., 2003). In some MSI-negative tumors, the relative
hierarchy of genetic and epigenetic alterations and their degree
of overlap remain to be determined.Figure 8. A ‘‘wear and tear’’ model for linking epigenetic and genetic alterations and gastrointestinal cancer pathogenesis through the age-dependent
accumulation of DNA demethylation
The figure illustrates the parallelism between this pathway (A) and the sequence of events occurring in MSI-positive tumors without mutator mutations (B). For
details, see text.CANCER CELL MARCH 2006
A R T I C L EExperimental procedures
Tumor samples
Eighty-six primary gastric cancers and 67 primary colon cancers with
matched normal tissue from patients who had undergone operation and
were collected as fresh-frozen tissues from the National Cancer Center Hos-
pital (Tokyo, Japan) and the Cooperative Human Tissue Network (USA), re-
spectively. Institutional Review Board approval was obtained to procure
and analyze the tissues used in this study.
AP-PCR DNA fingerprinting
Genomic DNA was prepared from tumor and normal tissues as described
previously. DNA (50–100 ng) was subjected to AP-PCR amplification in 25
ml of reaction mix: 1 unit of Taq DNA polymerase (Takara), 10 mM Tris HCl
(pH 8.3), 50 mM KCl, 5 mM MgCl2, and 1 mM primer. The nucleotide se-
quences of the primers BLUE and MCG1 are 50-CCGAATTCGCAAAGC
TCTGA-30 and 50-AACCCTCACCCTAACCCCAA-30, respectively. The reac-
tion was performed in a DNA Thermal Cycler (Perkin Elmer/Takara). The re-
action proceeded to the first 5-cycle incubation under conditions of low strin-
gency (94ºC for 30 s, 50ºC for 1 min, and 72ºC for 1.5 min), then to a 25-cycle
incubation under conditions of high stringency (94ºC for 15 s, 60ºC for 15 s,
and 72ºC for 1 min), and finally to an extension step (72ºC for 7 min). The PCR
products were electrophoresed in a 5.5% polyacrylamide gel containing 7 M
urea at 55 W for 5–6 hr. The dried gels were exposed to X-ray film at room
temperature overnight.
Quantitation of genomic alterations in tumors by AP-PCR
Independent DNA fingerprints were analyzed in duplicate or triplicate with
two arbitrary primers, MCG1 and BLUE. Sharp and clearly distinguishable
bands from the background in the fingerprints were considered for the as-
sessment of genomic alterations. Scoring of quantitative changes between
normal and tumor DNA was made by visual inspection as described previ-
ously. Whether the change was a gain (stronger band in tumor DNA) or
a loss (fainter band in tumor DNA), it was scored as one alteration. The
MCG1 and BLUE arbitrary primers yielded M score and B score, respec-
tively. The sum of M score and B score divided by the total number of bands
in each normal tumor pair fingerprint was the estimated GDF. The scoring of
signal intensity changes was done independently by two different observers.
Only alterations that were commonly detected by the two independent inves-
tigators were considered for the analysis. Furthermore, only changes com-
monly detected in at least two independent fingerprints with duplicates of
DNA from normal and tumor tissue (50–100 ng) were included. The fluctua-
tion of intensities among bands from normal tissue from different individuals
and the inter- and intra-assay reproducibility were within the same range as
colon tumors.
MS-AFLP
MS-AFLP was performed as described previously. Briefly, 1 mg of genomic
DNA was digested overnight with 5 units of methylation-sensitive NotI
(Roche, Indianapolis, IN) and 2 units of methylation-insensitive MseI (NE
Biolabs, Beverly, MA) at 37ºC. Two pairs of oligonucleotides were annealed
overnight at 37ºC to generate NotI (50-CTCGTAGACTGCGTAGG-30 and
50-GGCCCCTACGCAGTCTAC-30) and MseI (50-GACGATGAGTCCTGAG-30
and 50-TACTCAGGACTCAT-30) specific adaptors. The digested DNA was li-
gated to 1.25 ml each of 5 pmol/ml NotI and 50 pmol/ml MseI adaptor using
1 unit of T4 DNA ligase (Roche) overnight at 16ºC. A primer complementary
to the NotI adaptor (NotI primer, 50-GACTGCGTAGGGGCCGCG-30) was la-
beled at the 50 end using 32P-g-ATP (NEN) and T4 polynucleotide kinase
(Promega, Madison, WI). The adaptor-ligated template DNA was PCR ampli-
fied using three pairs of primers such as 32P-labeled NotI primer and one of
the not-labeled MseI primers (MseI-C, 50-GATGAGTCCTGAGTAAC-30; MseI-
CA, 50-GATGAGTCCTGAGTAACA-30; and MseI-CG, 50-GATGAGTCCTG
AGTAACG-30). A total of 20 ml PCR mixture consisted of 6 ng of 32P-labeled
NotI primer, 30 ng of MseI primer, 0.4 mM dNTP, and 1 unit of AmpliTaq
DNA polymerase (Perkin-Elmer, Foster City, CA). Two different amounts of
template DNA (2 ng and 4 ng) were used to confirm the reproducibility of
the results. The PCR started at 72ºC for 30 s and 94ºC for 30 s, then was fol-
lowed by 35 cycles of 94ºC for 30 s, 52ºC for 30 s, and 72ºC for 2 min. The
final extension was performed for 10 min at 72ºC. Each PCR sample was
electrophoresed on a denaturing gel (Sequagel-6, National Diagnostics,CANCER CELL MARCH 2006Atlanta, GA) after heat denaturing. The gel was dried and exposed to an
X-ray film.
Scoring of methylation alterations in tumors by MS-AFLP
Independent DNA fingerprints were analyzed in duplicate or triplicate with
three pairs of primers (NotI and MseI-C, NotI and MseI-CA, NotI and
MseI-CG). Only major bands in the fingerprints were assigned a number for
database construction and analysis. However, faint bands that showed clear
tumor-specific alterations in their intensity were also considered for the as-
sessment of methylation alterations for the stratification of tumors according
to their relative levels of methylation alterations or epigenomic damage frac-
tion (EDF) as for the GDF. A few bands that exhibited significant fluctuations
in their intensities among normal tissues from different individuals were not
scored. Scoring of quantitative changes between normal and tumor DNA
was made by visual inspection as described previously (Yamamoto et al.,
2001; Yamashita et al., 2003). The scoring of signal intensity changes was
done independently by two different observers using the same criteria as
for the AP-PCR alterations (Yamashita et al., 2003).
Coincidence of scoring in the common bands
The use of staggered primers for the MS-AFLP experiments allowed us to
have internal controls for the scoring of methylation alterations (both hyper-
and hypomethylation), because a significant percentage of the fingerprint
bands were common between the MseI-C and MseI-CA primers and be-
tween the MseI-C and MseI-CG primers. The percentage of bands with iden-
tical electrophoretic mobility was close to the theoretical 25% value (Sup-
plemental Data). The identity of some of the bands was confirmed by
sequencing of the bands after isolation from the MS-AFLP gels and reampli-
fication. Some of the bands were shown to be different despite their identical
mobility. The scoring of the alterations in 13 of the common bands indicated
that the concordance of scoring of the bands was about 95% (Supplemental
Data).
Microsatellite analysis
The MSI classification of the gastric and colon cancers used in this study was
previously done as part of a larger study on various molecular parameters in
gastric and colon cancer, using BAT26 and APD3 mononucleotide and
D1S158 dinucleotide microsatellite markers. Cases with alterations only in
the dinucleotide locus were considered MSI negative (i.e., MSI-L).
Sequencing analysis
Sequencing was performed as described previously. The PCR products
were eluted from the gels and amplified with the same primers used for
AP-PCR or MS-AFLP. Reamplified DNA was purified with QIAquick PCR pu-
rification kit (Qiagen) and sequenced with the ABI PRISM dye terminator cy-
cle sequencing kit (Perkin-Elmer).
Analysis of overall methyl-CpG content
Evaluation of methyl-CpG content was performed using a modified M.SssI
protocol (De Smet et al., 1996; Feinberg et al., 1988). DNA (100 ng) was
treated with 2 units of M.SssI methylase (CpG methylase, New England Bio-
Labs, USA) at 37ºC for 4 hr in 20 ml of buffer containing 0.75 mM S-adenosyl-
L-[methyl-3H]methionine (80.0 Ci/mmol, Amersham Biosciences, USA),
0.75 mM unlabeled S-adenosylmethionine, 50 mM NaCl, 10 mM Tris-HCl,
10 mM MgCl2, and 1 mM dithiothreitol. Reactions were inactivated by
20 min incubation at 75ºC. The methylated DNA was purified using a com-
mercially available silica-based purification kit (Geneclean kit, Q.BIOgene,
USA). This purification step provided a faster, easily scalable, and equally
efficient method compared to the previously described precipitation with tri-
chloroacetic acid and ethanol and subsequent filtration through GF/C filters.
Purified DNA was dissolved in 200 ml of water and transferred to a scintillation
vial with 2 ml of scintillation solution (EcoLume, ICN, USA). Incorporation of
the radioactive methyl group was measured using a Beckman liquid scintil-
lation counter. In parallel, a DNA methylation assay was performed using
the dam methylase. This enzyme methylates the deoxyadenosine within
the sequence GATC. The dam methylase assay allowed us to control the
quantity and quality of the DNA used in the M.SssI assay as well as the esti-
mation of the percentage of the methylated CpG in the sample. DNA (100 ng)
was incubated with 6 units of dammethylase in 20 ml of 0.75 mM S-adenosyl-
L-[methyl-3H]methionine (80.0 Ci/mmol, Amersham Biosciences, USA),205
A R T I C L E0.75 mM unlabeled S-adeonsylmethionine, 10 mM EDTA, 50 mM Tris-HCl,
and 5 mM 2-mercaptoethanol, at 37ºC for 4 hr. Inactivation and further steps
were equal to those performed with the M.SssI assay. All experiments were
performed in triplicate.
The percentage of methylated CpG was estimated from the ratio between
M.SssI anddammethylase 3H incorporation (M.SssI/dam ratio). Scanning the
human genome sequence available at the NCBI, we calculated that the ratio
of dam sites (GATC) to M.SssI sites (CG) is 0.2528. Considering equal effi-
ciencies for both enzymes, the percentage of methylated sites (mCpG%)
was estimated on the basis of the following equation:
mCpG% = ð12 0:25283M:SssI=dam ratioÞ3 100
Statistical analyses
All values were expressed as mean 6 standard deviation. Statistical differ-
ences between variables were analyzed with unpaired Student’s t tests or
analysis of variance, as appropriate. Survival distributions were calculated
by the Kaplan-Meier method using the log rank test. Univariate and multivar-
iate analyses were performed using the Cox proportional hazards model.
Supplemental data
The Supplemental Data include five supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/9/3/199/
DC1/.
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